A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Brief description of study

The purpose of this study is to test the safety and to define the appropriate dose of an investigational drug (CC-220) and an investigational combination of drugs. Investigational means that the drug or the combination of drugs is still being studied and that research doctors are trying to find out more. It also means that the US Food and Drug Administration (FDA) or any Health Authority has not approved CC-220 alone or in combination with other treatments for use in patients, including people with your type of disease (multiple myeloma).




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.